Read the December Us TOO Hotsheet

Click here to read these short Hotsheet articles:

  • Adjuvant ADT Best in Localized PCa Say Pooled Data
  • New PCa Staging System May Improve Pretreatment Prognostication
  • Active Surveillance for Black vs. White
  • Focal RT Boost in High-Risk PCa Cuts Biochemical Relapse Rate
  • Doc Moyad’s No Bogus Science: “Kiwi Rules!?”
  • Fall & Fracture Risk with Androgen Receptor Inhibitors (ARI) Treatment
  • Hood Technique & Post-RP Urinary Incontinence
  • Multiple Negative Prostate Biopsies in Men on Active Surveillance
  • Could Ipilimumab Have Benefit in Metastatic PCa After All?
  • SBRT Doubles Pain Response Over Usual RT in Spinal Metastases

 


Posted in Uncategorized by with no comments yet.

Read the November Us TOO Hotsheet

Click here to read these short Hotsheet articles:

  • Hold Off Radiotherapy After Prostate Cancer Surgery
  • Low BMD Testing Rates After Andro-gen Deprivation Therapy for PCa
  • A New AKT Inhibitor for PCa
  • Reserve PARP Inhibitors for Treating mCRPC with BRCA Mutations
  • Doc Moyad’s No Bogus Science: “Vote for Jicama – I Love Jicama!”
  • Black Men with PCa Found to Be Reluctant to Participate in Trials
  • Negative Trial Shows Overall Survival Benefit in mCRPC
  • Prognostic Impact of Intraductal Carci-noma of the Prostate (ICP)
  • More Prostate Cancers are Being Diagnosed at a Later Stage
  • Impact of Biopsy Compliance on AS Outcomes for PCa Patients

Posted in Uncategorized by with no comments yet.

Read the October Us TOO Hotsheet

Click here to read these short Hotsheet articles:

  • ADT & Favorable Intermediate-Risk PCa
  • Surgery Rates Doubled for High-Risk PCa
  • Less AS is Feasible with Some PCa
  • Racial Disparities for Men with PCa Post-RP
  • Rucaparib in mCRPC with BRCA1 or 2
  • Doc Moyad’s No Bogus Science Column: “A Supplement & CIPN = Yikes?!”
  • Under Treatment of PCa in Rural Locations
  • PCa & Bone Marrow Fatty Cells
  • Canary AS Study: MRI & High-Grade PCa
  • Prostate Mapping for US-Guided Biopsies
  • Delay by COVID-19 & RP Outcome?
  • HIFU Hemigland Ablation for PCa
  • House VA Committee Promotes PCa Care
  • Urine Extracellular Vesicle GATA2 mRNA
  • Oral Antiandrogens & Risk of Dementia
  • Darolutamide & Mortality for Men with PCa
  • Prostate Cancer in Young Men

Posted in Uncategorized by with no comments yet.

Read the September Us TOO Hotsheet

Click here to read these short Hotsheet articles:

  • A Call to Test Men with Prostate Cancer for COVID-19
  • Quality of Life Takes Huge Hit After Prostate Cancer Treatment
  • Genomic Profiles of PCa in Men of African and European Ancestry
  • Beyond PSA: New Prostate Cancer Screening Options
  • Doc Moyad’s No Bogus Science: “Weighing in on Weight Issues?!”
  • Can Grape Seed Extract Slow Prostate Cancer Spread?
  • Gleason Grade Group 2 Intermedi-ate Risk Prostate Cancer
  • Development & Validation of a Deep Learning Algorithm for Biopsies
  • Proof-of-Concept Study of Vaccine Shows Promise in Advanced PCa
  • Immune Checkpoint Inhibitors for PCa: Niche Role or Breakthrough?
  • RP with or without Neoadjuvant Chemohormonal Therapy in PCa

Posted in Uncategorized by with no comments yet.

Read the August Us TOO Hotsheet

Click here to read these short Hotsheet articles:

  • Prostate Cancer Mortality, Treatment in the US Differs by Region
  • BRCA2 Mutations Have Stronger Link to Cancer Than BRCA1
  • Benefits for PSA Test Screening Greater Than Generally Recognized
  • Enzalutamide and Survival in Non-metastatic CRPC
  • GNRH Antagonist vs. Agonist for Metastatic Prostate Cancer
  • Doc Moyad’s No Bogus Science: “Parking Fees at Cancer Centers!?”
  • New Focus on ADT in Prostate Cancer Guideline
  • Evaluation of Shorter RT Regimens for Breast & Prostate Cancers
  • Post-Dx BMI, Weight Change, PCa Mortality & Cardiovascular Disease
  • Cryotherapy – An Effective Treat-ment for Intermediate-Risk PCa?

Posted in Uncategorized by with no comments yet.

Read the July Us TOO Hotsheet

Click here to read these short Hotsheet articles:

  • Oral ADT Slashes Heart Risk in Advanced Prostate Cancer
  • Studies in Hormonal Therapy for Non-Metastatic CRPC (nmCRPC)
  • Testosterone Therapy Does Not Increase PSA Recurrence or Death
  • PCa Incidence 5 Years After USPSTF Nix on PCa Screening
  • Olaparib for Metastatic Castration-Resistant Prostate Cancer
  • Doc Moyad’s No Bogus Science Column: “PSA = People-Specific Antigen?!”
  • Consider Genetic Testing in All Metastatic Prostate Cancers
  • 18F-Fluciclovine PET in Men with BCR of Prostate Cancer After RP
  • PCa Trial Participants Shown to Be Overwhelmingly White
  • Benefit and Costs for Abiraterone vs. Enzalutamide in mCRPC
  • Post-Diagnosis BMI, Weight Gain & Mortality in Nonmetastatic PCa
  • Risk of PCa-Associated with Hereditary Cancer Syndromes

Posted in Uncategorized by with no comments yet.

Read the June Us TOO Hotsheet

Click here to read these short Hotsheet articles:

  • Time to Reassess Risks of Active Surveillance in Prostate Cancer?
  • Too Much RT Still Being Used for Bone Metastases
  • Randomized Trial of Conventional vs. Hypofractionated IMRT
  • Shared Decision Making & PSA-Based PCa Screening
  • Genomic Prostate Score (GPS) Results in the Canary AS Study
  • Doc Moyad’s No Bogus Science Column: “Intrusive Thoughts?”
  • RP Without Pelvic Lymph Node Dissection is Widely Practiced
  • Guest Column: Options for Urinary Incontinence After PCa Treatment
  • Darolutamide & ADT vs. ADT Alone in Non-Metastatic CRPC
  • Prostate SBRT Shows Positive Outcomes in Treatment of Low and Intermediate-Risk Disease

Posted in Uncategorized by with no comments yet.

Read the May Us TOO Hotsheet

Click here to read these short Hotsheet articles:

  • Defining a Role for Immunotherapy in mCRPC
  • Veteran’s Health Bill Promotes Comprehensive PCa Care Program
  • Prostatectomy of Mixed Mortality Benefit in Men with Prostate Cancer
  • Long-Term Unmet Supportive Care Needs of Prostate Cancer Survivors
  • AS vs. Immediate Treatment – Financial Incentives for Urologists
  • Doc Moyad’s No Bogus Science: “Are Low-Carb Diets Groovy Now!?”
  • Combined Biopsy Strategy Improved Prostate Cancer Diagnosis
  • 177Lu-PSMA Radionuclide Treatment in Men with Metastatic CRPC
  • PSMA PET/CT Better Detects Prostate Cancer Spread
  • Genomic Prostate Score Does Not Improve Risk Assessment
  • Its a Bust Adding Immunotherapy No Benefit in mCRPC

Posted in Uncategorized by with no comments yet.

Read the April Us TOO Hotsheet

Click here to read these short Hotsheet articles:

  • FDA Panel Thumbs Down for Cancer Focal Therapy
  • Apalutamide Benefit Sustained in Metastatic Castrate-Sensitive PCa
  • Hypofractionate RT for PCa Stands the Test of Time
  • Enzalutamide, ADT and Salvage RT in High-Risk PSA-Recurrent PCa
  • Robotic-Assisted RP & Persistent Postoperative Opioid Use
  • Doc Moyad’s No Bogus Science: “Heart Healthy = Immune Healthy = Prostate Healthy!?”
  • The Cost of Bottling Up Emotions
  • Sunitinib, Docetaxel & Prednisone in Chemo-Naïve Metastatic CRPC
  • Less Frequent Prostate Cancer Screening a Good Idea
  • Guest Column: Goodbye Poke and Hope!
  • HSD3B1 Genotype Tied to Prostate Cancer Outcomes

Posted in Uncategorized by with no comments yet.

Read the March Us TOO Hotsheet

Click here to read these short Hotsheet articles:

  • Lower Out-of-Pocket Costs for Robotic Cancer Surgery
  • More Radium-223 in mCRPC Means More Toxicity
  • Stalling ADT Use in Recurrent PCa
  • Validation of Gallium-68 PSMA PET/CT for Primary PCa Staging
  • Long-Term Follow-Up in Low-Dose-Rate Brachytherapy for PCa
  • Doc Moyad’s No Bogus Science: “Lorcaserin Bites the Dust!?”
  • Apalutamide & Overall Survival in Non-Metastatic CRPC
  • Pembrolizumab for Treating Refractory Metastatic CRPC
  • PET Spots Prostate Cancer Metastases Missed on CT, MRI
  • Modest Survival Gains Shown in Newly Diagnosed Metastatic PCa
  • Long-Term Outcomes in Gleason Grades 2 & 3 PCa with AS
  • Guest Column: Staying Sexually Active After PCa Treatment
  • Earlier Cabazitaxel Use in mCRPC

 


Posted in Uncategorized by with no comments yet.